CytomX Therapeutics and ImmunoGen to Develop Probody-Drug Conjugates - - BioPharm International

ADVERTISEMENT

CytomX Therapeutics and ImmunoGen to Develop Probody-Drug Conjugates


CytomX Therapeutics, a probody therapeutics company, and ImmunoGen, a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, have entered into a collaboration to develop probody-drug conjugate (PDC) therapies for the treatment of cancer.
Under the terms of the agreement, the companies will collaborate to develop PDCs against a defined number of targets. This collaboration brings together CytomX’s proprietary antibody masking technology and tumor-selective protease substrates with ImmunoGen’s ADC cell-killing agents and engineered linkers.

According to a press statement, each company retains full development control of PDC compounds resulting from its target selection and is responsible for preclinical and clinical testing, manufacturing, and commercialization. Each company is entitled to potentially receive clinical and post-approval milestone payments from the other company, as well as royalties on the sales of any marketed products resulting from this collaboration.  

Source: CytomX Therapeutics

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

European Commission Approves RoACTEMRA for Treatment of RA
September 9, 2014
PDA Announces Technical Report on Drug Shortages
September 9, 2014
Infinity and AbbVie Collaborate to Develop Oncology Drug
September 5, 2014
Merck KGaA Breaks Ground on Facility in China
September 5, 2014
DPT Laboratories Acquires Media Pharmaceuticals' Lakewood Facilities
September 5, 2014
Author Guidelines

Click here